Bringing the Ovarian Cancer Test to Market

An ovarian cancer assay based on protein pattern analysis is arousing excitement in a field all too often met with disappointment. Given initial excitement over the test and protein pattern analysis in general, business activity is likely to follow shortly. The NCI, FDA and a start-up, Correlogic Systems, are developing the test and taking it to large clinical trials this summer. Correlogic claims to have broad patents on pattern analysis for diagnostic purposes, a contention that is sure to lead to controversy, given the apparently high stakes.

The use of protein pattern arrays to detect early-stage cancer is one of the most intriguing recent advances in cancer diagnostics. In preliminary clinical studies, a series of tests aimed at early detection of a variety of cancers seem to demonstrate the approach's high specificity and sensitivity. Arousing particular excitement in a field all too often met with disappointment and false promises is an ovarian cancer assay, whose results were published in the February issue of The Lancet. A study of roughly 100 high-risk women found the test picked up normally undetectable early-stage ovarian cancer in 100% of patients. (See "Overcoming Skepticism in Cancer Diagnostics," START-UP, May 2002 Also see "Overcoming Skepticism About Cancer Diagnostics" - Medtech Insight, 1 May, 2002..)

Given the compelling clinical aspects, business activity certainly won't be far behind. If protein patterns turn out to have as much value as preliminary data suggests, those who hold IP...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

 
• By 

BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.

Industry Execs Talk Tariff Turbulence During MD&M East

 

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Business

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

 
• By 

BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By 

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.